岩舒注射液联合化疗治疗晚期非小细胞肺癌36例疗效观察

目的观察岩舒注射液联合NP方案在晚期非小细胞肺癌（NSCLC）中的作用效果。方法将2006-5至2008-5就诊于我院的72例晚期非小细胞肺癌患者随机分为治疗组、对照组,各36例,治疗组给予岩舒注射液联合NP化疗方案治疗,对照组给予NP化疗方案化疗,观察化疗效果及化疗毒性反应变化。结果治疗组和对照组的总RR分别为38.9%和16.7%（P〈0.05）,总临床受益率（CBR）分别为75.0%和55.6%（P〉0.05）,治疗组消化道毒性反应及骨髓抑制均低于对照组（P〈0.01）。结论岩舒注射液能增强晚期非小细胞肺癌（NSCLC）患者的化疗效果,降低毒性反应,提高生活质量。

Therapeutic efficacy of Yanshu injection combined with NP chemotherapy in treantment of advanced non-small cell lung cancer in 36 cases

Objective To observe the therapeutic efficacy of Yanshu injection in combination with NP Chemotherapy for advanced non-small cell lung cancer. Methods 72 patients at our hospital, from May 2006 to May 2008 with advanced non-small cell lung cancer were randomly divided into treatment group and control group, the treatment group received Yanshu injection combined with NP chemotherapy NP, the control group to receive NP chemotherapy alone. Clinical effects and toxicity of chemotherapy were observed. Results The total RR of treatment group and control group were 38.9% of and 16. 7% （P 〈0. 05） , the total clinical benefit rate （CBR） were 75.0% and 55.6% respectively （P 〉 0. 05 ）. And in treatment group, inhibition of gastrointestinal toxicity and bone marrow were lower than that in the control group （ P 〈 0.01 ）. Conclusion Yanshu injection enhanced with advanced non-small cell lung cancer （NSCLC） patients with chemotherapy to reduce toxicity and improve quality of life.